Transfection News and Research

RSS

Using Spherical Nucleic Acids to Track and Treat Disease

Spherical nucleic acids are structures that are made by taking a nanoparticle template and using chemistry to arrange short strands of DNA or RNA on the surface of those particles. The spherical core of the nanoparticle creates a spherical arrangement of DNA or RNA, similar to tiny little balls of nucleic acids.

From Pittcon 1 Mar 2017

Review shows lipid nanoparticles as highly promising delivery systems in gene therapy

Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.

14 Feb 2017

IDT offers cost-effective and most complete spectrum of CRISPR genome editing systems

Reflecting its drive to provide innovative solutions to the genomics community, Integrated DNA Technologies (IDT) is the first genomics company to develop and bring to market a complete ribonucleoprotein-based Cpf1 CRISPR system.

2 Feb 2017

New IDT webinar to highlight benefits of using RNP complexes for efficient genome modifications

Integrated DNA Technologies will host an informative webinar entitled ‘Ribonucleoprotein delivery of CRISPR-Cas9 reagents for increased gene editing efficiency’ on December 14, 2016.

9 Dec 2016

Synthetic sgRNA for CRISPR genome editing

Chemically synthesized single guide RNA is the best way to do CRISPR genome editing. It is more pure than biological methods of creating guide RNAs, like in vitro transcription or plasmids. As a result, sgRNA leads to more consistency and higher quality.

8 Dec 2016

Synthego introduces CRISPRevolution synthetic sgRNA kit for fast, high-throughput gene editing

Synthego, a leading provider of genome engineering solutions, today announces the world’s first synthetic single guide RNA (sgRNA) CRISPR genome editing kit.

24 Sep 2016

Studying mutant peptides may help detect weaknesses in tumor cells

Researchers from MIPT, the Institute of Biomedical Chemistry, the Institute for Energy Problems of Chemical Physics, and the Research Institute of Physico-Chemical Medicine have presented an algorithm to detect mutant proteins based on mass spectrometry data and the results of exome sequencing.

29 Aug 2016

Former SpaceX engineers launch Synthego, CRISPRevolution to accelerate genome engineering research

Synthego, a leading provider of genome engineering solutions, officially launches today. Synthego’s flagship product line, CRISPRevolution, features synthetic guide RNA products designed to accelerate CRISPR/Cas9 and Cpf1 genome engineering research. CRISPRevolution is the first product line to offer economical access to fully synthetic RNA for high fidelity editing and increased precision in genome editing.

12 Aug 2016

NYU dentists receive grant to test whether non-viral gene delivery can effectively treat oral cancer pain

The National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, has awarded Drs. Brian Schmidt and Seiichi Yamano a $1.2M (3-year) grant to test whether their non-viral gene delivery method can effectively and safely treat oral cancer pain.

28 Jun 2016

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).

18 May 2016

Synpromics, Cell Therapy Catapult to create stable producer cell lines for large-scale manufacture of viral vectors

Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and increasing the scale and efficiency of viral vector manufacturing.

12 Jan 2016

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Scalable production of gene therapy vectors: an interview with Frank Ubags

Gene therapy involves introducing genetic material into cells to replace missing or malfunctioning genes or to add a gene to express a beneficial protein in order to treat certain diseases, such as cancer or inherited disorders.

26 Oct 2015

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis will combine their unique and proprietary Oligoclonics® and SUREtechnology™ platforms respectively to develop a product combining two bispecific full length IgG antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases...

20 May 2015

A beginner’s guide to CRISPR genome editing

In a recent DECODED Online entry, Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, provides an overview of the CRISPR/Cas9 system to scientists looking to enhance their genome modification strategy in model organisms or cell lines.

From Integrated DNA Technologies 14 Apr 2015

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Sigma-Aldrich Corporation today announced that SAFC Commercial, its custom manufacturing services business unit, has entered a commercial sales and service contract with leading biopharmaceutical company, BeiGene.

11 Mar 2015

Finding may help advance experimental approach to improving public health

Scientists have discovered a new way to manipulate how cells function, a finding that might help advance an experimental approach to improving public health: DNA vaccines, which could be more efficient, less expensive and easier to store than traditional vaccines.

5 Mar 2015

Choosing the best way to verify the quality and quantity of Chromatin Immunoprecipitation DNA

Porvair Sciences has published a new guide to help laboratories choose the best way to verify the quality and quantity of their Chromatin Immunoprecipitation (ChIP) DNA.

From Chromatrap® - Porvair Sciences Ltd 25 Nov 2014

Study findings have potential to advance treatments for small cell lung cell cancer

Two recently published studies by a research team at University Hospitals Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

26 Sep 2014

GW researcher awarded grant to develop a model system to study PN infection

According to a recent World Health Organization report of the leading causes of death worldwide, one-third of all deaths are due to infectious and parasitic diseases. There are currently no vaccines for parasitic nematode (PN), or worm infections in humans, and development of new drugs and vaccines will stall until researchers have a better understanding of PN biology.

11 Aug 2014